Guggenheim Initiates Coverage On Alpine Immune Sciences with Buy Rating, Announces Price Target of $55
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan initiates coverage on Alpine Immune Sciences (ALPN) with a Buy rating and a price target of $55.
April 09, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Vamil Divan has initiated coverage on Alpine Immune Sciences with a Buy rating and set a price target of $55.
The initiation of coverage by a reputable analyst with a Buy rating and a significant price target suggests a positive outlook for Alpine Immune Sciences. This could lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100